| Roger G. Worthington P.C. | 800.831.9399 | Search |
 |
||||||||||||||||||||||||||||||||||||||||||||||||
| Helping Asbestos Victims Get Justice in the Courtrooms and Help in the Hospitals since 1990. | ||||||||||||||||||||||||||||||||||||||||||||||||
|
Expand All | Contract All Empower Yourself: Free Medical/Legal Guide |
||||||||||||||||||||||||||||||||||||||||||||||||
 PATIENT PROFILES
California State Rock
Empower Yourself
PHLBI
Mesothelioma
Meso Causation
Meso Diagnosis
Treatment Options
Treatment Centers
Litigation
Settlements/Verdicts
Patient Advocacy
Asbestos Products
Legislative Updates
Meso Hotspots
Lung Cancer
Why You Need RGWPC
Web Links
|
Chemotherapy
May Not Affect Survival or Quality of Life
for Patient with Advanced Mesothelioma Cancer Consultants http://professional.cancerconsultants.com/oncology_main_news.aspx?id=42007 Researchers from the UK and Australia involved in a multicenter randomized trial have concluded that chemotherapy for advanced pleural mesothelioma may not improve survival or quality of life. The details of this study appeared in the May 17, 2008 issue of The Lancet.1 Pleural mesothelioma is a rare and lethal form of cancer caused by asbestos exposure. There are about 2,500 new cases a year in the United States. Because the disease is often advanced at the time of diagnosis, average survival for those with pleural mesothelioma has been significantly less than one year. Recent studies have suggested that chemotherapy can improve quality of life and prolong survival compared with supportive care measures. The current study compared active symptom control (ASC), with one of two chemotherapy regimens (mitomycin, vinblastine, and cisplatin [MVP] or vinorelbine alone) in 409 patients with advanced pleural mesothelioma. The following table summarizes the main findings of this trial.
*** POSTED JUNE 4, 2008 *** |
|||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
